GlassScriptPhysician profile
Luay Sarsam
NPI 1558744953
$12,039.96
in general payments reported to CMS, 2019-2025
33 companies · $1,847 in 2025
The $1,847 reported for 2025 was more than what 82% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $590 · 2020: $326 · 2021: $1,091 · 2022: $3,784 · 2023: $2,559 · 2024: $1,842 · 2025: $1,847.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,701 · Travel and Lodging: $348 · Consulting Fee: $200.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,700.92 |
| Travel and Lodging | $348.03 |
| Consulting Fee | $200.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $4,368.47 | 2019-2025 | Cardiomems, Jot Dx, Mitraclip |
| Cvrx, INC. | $972.59 | 2023-2025 | Barostim Neo System |
| Abiomed | $814.32 | 2021-2025 | Impella |
| Astrazeneca Pharmaceuticals LP | $736.90 | 2019-2024 | Wainua, Brilinta, Farxiga |
| Heartflow, INC. | $685.09 | 2024-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $645.19 | 2019-2024 | Lifevest |
| Alnylam Pharmaceuticals INC. | $601.22 | 2023-2025 | Amvuttra |
| Bayer Healthcare Pharmaceuticals INC. | $547.20 | 2021-2025 | |
| Actelion Pharmaceuticals US, INC. | $417.41 | 2022-2024 | Opsumit, Uptravi |
| Edwards Lifesciences Corporation | $335.36 | 2019-2025 | Sapien 3 Ultra Resilia |
| Boston Scientific Corporation | $302.61 | 2023-2024 | Versacross Access Solution |
| Novartis Pharmaceuticals Corporation | $294.26 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $288.36 | 2023-2025 | Verquvo, Winrevair, Dificid |
| Boehringer Ingelheim Pharmaceuticals, INC. | $169.77 | 2023-2025 | Jardiance |
| United Therapeutics Corporation | $144.30 | 2021 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $138.00 | 2023-2025 | Camzyos, Eliquis |
| Janssen Pharmaceuticals, INC | $101.01 | 2020-2022 | |
| Kestra Medical Technology Services, INC. | $92.27 | 2024-2025 | Assure Wcd |
| Nuwellis, INC. | $77.50 | 2023 | Aquadex Smartflow Console |
| Kiniksa Pharmaceuticals International, Plc | $63.01 | 2024 | Arcalyst |
| Kiniksa Pharmaceuticals, LTD. | $37.82 | 2023 | Arcalyst |
| Scpharmaceuticals INC. | $32.20 | 2024 | |
| Alexion Pharmaceuticals, INC. | $22.49 | 2019 | |
| Pfizer INC. | $21.57 | 2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $19.78 | 2025 | Caplyta |
| Amgen INC. | $15.46 | 2025 | Repatha |
| Glaxosmithkline, LLC. | $15.24 | 2025 | Arexvy |
| Bridgebio Pharma, INC. | $15.05 | 2025 | Attruby |
| Daiichi Sankyo INC. | $14.89 | 2023 | Injectafer |
| Lantheus Medical Imaging, INC. | $14.20 | 2019 | |
| Novo Nordisk INC | $13.65 | 2022 | |
| Medtronic Vascular, INC. | $11.44 | 2020 | |
| Portola Pharmaceuticals, LLC | $11.33 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Luay Sarsam listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.